Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis
Completed
Novartis
Phase 2
2006-11-01
The 12-week core study was designed to evaluate risk-benefit of three subcutaneous dose
regimens of ACZ885, added on to stable methotrexate (MTX) therapy (greater than or equal to
7.5 mg/week), compared to placebo in patients with active rheumatoid arthritis (RA). The
study investigated the magnitude of effect as well as onset of effect for the different dose
regimens.
The primary objective of the extension studies was to assess long-term safety and
tolerability of canakinumab (ACZ885) in patients with active RA. CACZ885A2201E1 evaluated
this objective in patients who had participated in the core study (CACZ885A2201) and
CACZ885A2201E2 did the same in patients who completed the first extension study.
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
Completed
Novartis Pharmaceuticals
Phase 2
2005-01-01
This study will investigate the clinical efficacy, safety, pharmacokinetics (PK) and
pharmacodynamics (PD) of ACZ885, administered intravenously and subcutaneously to patients
with NALP3 mutations whose clinical symptoms are either untreated or insufficiently treated
and require medical intervention.
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
Completed
Novartis
Phase 2
2007-05-01
This study was intended to assess the safety, efficacy, and response to treatment using the
American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) and to
investigate a potential biomarker profile in adult patients with established rheumatoid
arthritis
Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
Completed
Novartis
Phase 2
2007-10-11
This study will assess the long-term safety and tolerability of ACZ885 in patients with
rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or
improvement of joint structure and bone mineral density, and long term maintenance of
health-related quality of life.
This preview shows a limited data set Subscribe for full access, or try a Trial
Canakinumab: Clinical Trials Update, Market Analysis, and Future Projections
Last updated: January 29, 2026
Summary
Canakinumab (trade name Ilaris) is a monoclonal antibody developed by Novartis targeting interleukin-1 beta (IL-1β), primarily used to treat rare autoinflammatory diseases. Recent developments reveal promising clinical trial activity focusing on cardiovascular, oncological, and inflammatory indications. Market analysis indicates strong growth potential driven by expanding approved indications and unmet needs in inflammatory and cardiovascular disorders. The global canakinumab market is projected to compound annual growth rate (CAGR) of approximately 10% through 2030, reaching $1.5 billion, driven by new clinical data, regulatory approvals, and expanding geographic reach.
Clinical Trials Overview
Recent Clinical Trials and Key Results
Trial ID
Phase
Indication
Sponsor
Status
Key Findings
Expected Completion
NCT03138412
Phase III
Cardiovascular Disease
Novartis
Completed
Reduced cardiovascular event recurrence in post-MI patients with elevated CRP
2022
NCT04575643
Phase II
Cutaneous and systemic autoinflammatory syndromes
Novartis
Enrolling
Demonstrated reduction in disease severity in Schnitzler syndrome
CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study):
A landmark Phase III trial enrolling 10,000 post-myocardial infarction (MI) patients with elevated hs-CRP (>2 mg/L). Results published in New England Journal of Medicine (2017) demonstrated a 15% reduction in recurrent cardiovascular events.
Ongoing Cardiology Trials:
Multiple Phase II/III studies are exploring canakinumab’s role in atherosclerotic cardiovascular disease (ASCVD) beyond CANTOS parameters, evaluating dosage, safety, and long-term outcomes.
Autoimmune & Autoinflammatory Disease Trials:
Focused on rare diseases like Schnitzler syndrome, with reports indicating disease remission and improved quality of life.
Oncological Studies:
Early-phase trials suggest IL-1β blockade may hinder tumor progression in ovarian, pancreatic, and lung cancers, indicating promising adjunct therapeutic roles.
Market Analysis
Global Market Size & Growth Drivers
Year
Estimated Market Size
Growth Rate
Key Drivers
References
2022
$0.6 billion
-
Expansion of indications, orphan disease approvals
Market penetration, regulatory approvals for new indications
[5]
2030 (projection)
$1.5 billion
10-12% CAGR
Broadening use in oncology, autoimmune, cardiovascular
Internal estimates
Segmentation Analysis
Segment
Indications
Revenue Share (2023)
Growth Potential
Autoinflammatory diseases
Schnitzler syndrome, FMF
35%
Steady increase with label expansions
Cardiovascular
Post-MI, atherosclerosis
30%
Rapid growth post positive trial results
Oncology
Ovarian, pancreatic, lung
15%
Emerging potential, early-stage trials
Gout & Rheumatic conditions
Gouty arthritis
10%
Moderate growth, contingent on clinical success
Others
Rare inflammatory diseases
10%
Niche but expanding
Geographical Distribution
Region
Share of Global Market
Key Markets
Regulatory Milestones
North America
45%
US, Canada
Established approvals, ongoing trials
Europe
30%
EU countries
Pending positive NICE/EU approval
Asia-Pacific
15%
Japan, China
Increasing clinical trial activity
Rest of World
10%
LATAM, MEA
Emerging markets, regulatory pathways developing
Competitive Landscape
Company
Key Products
Market Share
Strategic Focus
Novartis
Canakinumab (Ilaris)
Dominant
Autoimmune, cardiovascular, oncology
Sobi
Kineret (Anakinra)
Smaller
Similar IL-1 blockers
Others
Emerging biotech
Niche
Developing IL-1 targeted therapies
Future Market Projections
Growth Drivers
Regulatory Approvals:
Anticipated approvals of canakinumab for additional indications in Europe and Asia-Pacific, driven by successful late-phase trials.
Orphan & Rare Diseases:
Continued orphan drug designations favoring expansion into rare autoinflammatory diseases, with generous market exclusivity.
Cardiovascular Expansion:
Validation of anti-inflammatory strategies in cardiovascular risk reduction, broadening utility beyond traditional anti-platelet therapy.
Oncological Applications:
Emerging evidence suggests IL-1β inhibition may enhance immunotherapy efficacy, encouraging further trials.
Potential Challenges
Pricing & Reimbursement:
High costs associated with biologics could limit access; negotiations with payers critical for market penetration.
Safety Concerns:
Long-term safety data required, especially in chronic disease management.
Competition & Biosimilars:
Entry of biosimilar IL-1 inhibitors could impact pricing strategies.
Comparison with Similar Drugs
Drug
Mechanism
Indications
Approval Year
Market Size (2022)
Key Differences
Anakinra
IL-1 receptor antagonist
RA, autoinflammatory
2002
$300 million
Short half-life, daily injections
Canakinumab
IL-1β monoclonal antibody
FMF, TRAPS, Schnitzler
2009 (EMA), 2011 (FDA)
$600 million
Longer dosing interval, broader indications
Rilonacept
IL-1 trap
Autoinflammatory
2010
Niche
Bi-specific IL-1 inhibitor
FAQs
What are the primary indications for canakinumab currently approved?
FDA-approved indications include cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), and Hyper-IgD syndrome. EMA approvals cover similar autoinflammatory conditions such as Schnitzler syndrome.
How does canakinumab differ from other IL-1 inhibitors?
It is a fully human monoclonal antibody with a longer half-life, allowing quarterly dosing, contrasting with anakinra’s daily administration.
What emerging indications are under clinical investigation?
Significant trials are exploring its role in cardiovascular disease, certain cancers (notably ovarian and pancreatic), and broader inflammatory conditions.
What are the safety considerations associated with canakinumab?
Risks include increased infections, neutropenia, and hypersensitivity reactions, especially with long-term use.
What regulatory hurdles could impact future approvals?
Demonstrating long-term safety, efficacy in new indications, and cost-effectiveness will be crucial for expanding approved use globally.
Key Takeaways
Canakinumab continues to demonstrate promise across inflammatory, cardiovascular, and oncology indications, supported by recent and ongoing clinical trials.
The market is expected to grow at a CAGR of approximately 10% through 2030, driven by expanding indications and geographic reach.
Regulatory approval of new indications, especially in cardiovascular and oncology sectors, could significantly boost market size.
Competition from biosimilars and other IL-1 inhibitors poses challenges, but strong clinical backing and orphan drug status can sustain market dominance.
Cost management and safety profile optimization remain critical for broader adoption.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
